MEDIMMUNE UK LIMITED – MIA(IMP) 19437
| Authorisation Number | UK MIA(IMP) 19437 |
| Category | MIA(IMP) |
| Holder | MEDIMMUNE UK LIMITED |
| Registered Address | MEDIMMUNE UK LIMITED, PLOT 6 RENAISSANCE WAY, BOULEVARD INDUSTRY PARK, SPEKE, LIVERPOOL, L24 9JW, UNITED KINGDOM |
| Authorisation Date | Apr 23, 2026 |
| Legal Basis | InvestigationalPart 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 [SI 2004/1031] |
| Sites | 1 |
| Manufacturing Operations | 1.1 1.1.1 1.1.1.6 1.3 1.3.1 1.3.1.2 1.3.2 1.3.2.2 1.4 1.4.2 1.4.2.1 1.6 1.6.1 1.6.2 1.6.3 1.6.4 |
| Importation Operations | 2.1 2.1.1 2.1.2 2.1.3 2.1.4 2.2 2.2.1 2.2.1.1 2.2.3 2.2.3.8 2.3 2.3.1 |
| MHRA Link | View on MHRA Website |
Sites (1)
MEDIMMUNE UK LIMITED
BOTH
Country: UNITED KINGDOMProduct Class: Human Investigational Medicinal Products
Manufacturing
1.1 — Sterile Investigational Medicinal Products
1.1.1 — Aseptically prepared (processing operations for the following dosage forms)
1.1.1.6 — Other aseptically prepared products
1.3 — Biological investigational medicinal products
1.3.1 — Biological medicinal products
1.3.1.2 — Immunological products
1.3.2 — Batch certification
1.3.2.2 — Immunological products
1.4 — Other investigational medicinal products or manufacturing activitiy
1.4.2 — Sterilisation of active substances/excipients/finished products:
1.4.2.1 — Filtration
1.6 — Quality control testing
1.6.1 — Microbiological: sterility
1.6.2 — Microbiological: non-sterility
1.6.3 — Chemical/Physical
1.6.4 — Biological
Importation
2.1 — Quality control testing of imported medicinal products
2.1.1 — Microbiological: sterility
2.1.2 — Microbiological: non-sterility
2.1.3 — Chemical/Physical
2.1.4 — Biological
2.2 — Batch certification of imported medicinal products
2.2.1 — Sterile Products
2.2.1.1 — Aseptically prepared
2.2.3 — Biological medicinal products
2.2.3.8 — Other biological medicinal products
2.3 — Other Importation Activities
2.3.1 — Site of Physical Importation
Content Preview
The source document is available on KeyPedia. Sign in to view.